1 Institute of Signaling, Developmental Biology and Cancer Research, CNRS UMR-6543, Centre Antoine Lacassagne, 06189 Nice, France
2 Serono Pharmaceutical Research Institute, Ares-Serono International SA, 1228 Plan-les-Ouates, Geneva, Switzerland
*Author for correspondence (e-mail: volmat{at}unice.fr)
Accepted June 25, 2001
![]() |
SUMMARY |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key words: Growth factors, Signal transduction, Protein kinases, Protein phosphatases, Cell nucleus
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Although the mechanisms of activation of p42/p44 MAPKs are relatively well described, little is known about the mechanisms of inactivation. Different phosphatases have been implicated in the rapid inactivation of p42/p44 MAPKs such as the serine/threonine-specific phosphatase PP2A (Alessi et al., 1995; Sohaskey and Ferrell, 1999) and several related tyrosine-specific phosphatases PTP-SL, STEP, He-PTP and LC-PTP, which show a good specificity towards p42/p44 MAPKs (Oh-hora et al., 1999; Pettiford and Herbst, 2000; Pulido et al., 1998; Saxena et al., 1999; Zuniga et al., 1999). However, dual specificity phosphatases can specifically dephosphorylate both the tyrosine and the threonine residues of MAPKs. These MAPK phosphatases (MKPs) have different subcellular localizations and diverse specificities for the MAPKs (Camps et al., 2000; Keyse, 2000). Among them, MKP1 and MKP2 are induced by the p42/p44 MAPK pathway (Brondello et al., 1997), stabilized by p42/p44 MAPKs phosphorylation (Brondello et al., 1999) and located exclusively in the nucleus (Brondello et al., 1995). However, the in vivo implication of these MKPs has never been clearly demonstrated in the long-term regulation of p42/p44 MAPKs.
With the emergence of antibodies that recognize exclusively the dually phosphorylated TEY sequence (Yung et al., 1997) of the activating loop of p42/p44 MAPKs (Anderson et al., 1990; Payne et al., 1991), it was of great interest to focus on the active p42/p44 MAPKs pool and to follow its spatial and temporal regulation during growth factor stimulation. Here, we report that both non-mitogenic and mitogenic agonists induce the rapid entry of phosphorylated p42/p44 MAPKs into the nucleus. However, during long-term stimulation, the active nuclear p42/p44 MAPKs pool progressively decreases and, after 3 hours of stimulation, p42/p44 MAPKs accumulate massively in the nucleus but in an inactive state. We show that the phosphatases involved in this nuclear inactivation have a tyrosine or a dual specificity, they are neo-synthesized following activation of the p42/p44 MAPKs pathway and their action is dependent on their binding to p42/p44 MAPKs via a specific docking site. Presently, the only nuclear phosphatases that fulfill all these criteria are the MKPs. Therefore we propose that they are the best candidates for this inactivation process. Although, p42/p44 MAPKs permanently shuttle between the cytoplasm and the nucleus during mitogenic stimulation, we propose that progressive sequestration of p42/p44 MAPKs in a nuclear anchoring and inactivating center, away from the cytoplasmic Raf>MEK activating center is an efficient mechanism for signal termination.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Indirect immunofluorescence
After growth on glass coverslips, G0-arrested cells were treated as described in the Results and in figure legends. Indirect immunofluorescence analysis was performed as previously described (Lenormand et al., 1998). For anti-activated p42/p44 MAPKs staining, cells were fixed with 10% paraformaldehyde and permeabilized in 20°C methanol. For anti-p42/p44 MAPKs staining we used methanol/acetone 70/30 (v/v) at 20°C for fixation and permeabilization. The following antibodies were used: monoclonal antibody anti-activated p42/p44 MAPKs (Sigma #M8159; 1:200); polyclonal antibody anti-p42/p44 MAPKs (UBI #06-182; 1:1000); polyclonal antibody anti-BSA (a gift from J. C. Chambard; 1:300); biotin-coupled anti-rabbit antibody (Amersham; 1:500); Alexa-594 coupled anti-mouse antibody (Molecular Probes; 1:250) and FITC-coupled streptavidin (1:500).
All observations were performed with a DMR Leica microscope using a x100 lens, except for Fig. 6, for which observations were performed with a x63 lens. Confocal microscopy was performed using a DMR Leica confocal microscope with a x100 lens and optical sections were taken every 2.5 µm.
|
Microinjection
Microinjection was performed using an inject+matic microinjector (Geneva, Switzerland) and an MO-188 micromanipulator (Narishige) mounted on an inverted Nikon diaphot TMD microscope. Capillaries (GC120F-10) were purchased from Harvard Apparatus (Endenbridge, UK). BSA-coupled peptides were dissolved in injection buffer (10 mM Hepes-KOH, pH 7.4) at a concentration of 12 mg/ml.
Phosphatase activity assay
Phosphatase activity was measured as previously described (Nichols et al., 2000).
Materials
Chemicals of the highest purity available were purchased. Leptomycine B was a generous gift from B. Wolff-Winiski, Novartis Forschungsinstitut, Vienna, Austria. bpV(phen) was from Calbiochem and UO126 from Promega. Peptides were synthesized and coupled to BSA (average of seven peptides per BSA molecule) by Neosystem, Strasbourg, France.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
We conclude that both mitogenic and non-mitogenic agonists can trigger the rapid entry of phosphorylated p42/p44 MAPKs into the nucleus with nearly identical time courses. However, the activation of p42/p44 MAPKs is briefer with non-mitogenic agonists with an extinction of the signal both in the nucleus and in the cytoplasm within 15 minutes of stimulation.
Long-term activation of p42/p44 MAPKs induces their nuclear accumulation in the dephosphorylated form
Fig. 2A shows serum stimulation up to 9 hours. Whereas p42/p44 MAPKs remained active for up to 6 hours in the cytoplasm, a rapid decline of the nuclear active forms occurred from 10 minutes to 1 hour of stimulation. After 3 or 6 hours of serum stimulation, phosphorylated p42/p44 MAPKs were no longer detectable in the nucleus and gradually disappeared in the cytoplasm. This result was rather unexpected since p42/p44 MAPKs progressively accumulate in the nucleus during serum stimulation (Chen et al., 1992; Lenormand et al., 1998). Therefore, it was of great interest to follow the localization of active p42/p44 MAPKs in cells where the p42/p44 MAPKs activity is artificially maintained at an elevated level. In cells stably expressing the Raf1:ER chimera, the activation of
Raf1:ER chimera with estradiol induces persistent activation of the p42/p44 MAPKs pathway (Lenormand et al., 1998; Samuels et al., 1993). Indeed, in these cells,
Raf1:ER chimera stimulation induces a persistent staining of active p42/p44 MAPKs in the cytoplasm from 10 minutes up to 9 hours. Nevertheless, in the nucleus, staining for the phosphorylated forms of p42/p44 MAPKs was greatly reduced at 1 hour and not detectable from 3 to 9 hours of
Raf1:ER chimera stimulation (Fig. 2B).
|
Similar time courses of nuclear p42/p44 MAPKs translocation and specific inactivation of the nuclear pool were observed in all cells tested so far, including mouse vascular endothelial cell line (1G11), primary mouse embryo fibroblasts (MEF), rat embryo fibroblasts (REF 52), Hela cells and mouse vascular smooth muscle cells (data not shown).
Tyrosine phosphatases inhibitors prevent p42/p44 MAPKs inactivation in the nucleus
To characterize the phosphatases responsible for the nuclear inactivation of p42/p44 MAPKs, we used bpV(phen) (1 mM), also called oxovanadate, a potent tyrosine phosphatase inhibitor (Bevan et al., 1995; Posner et al., 1994). After 3 hours of serum stimulation, nuclear p42/p44 MAPKs were inactive (Fig. 3a). Treatment of these cells with 1 mM bpV(phen) led to the reappearance of nuclear phosphorylated p42/p44 MAPKs within 5 minutes (Fig. 3b). After a 10 or 15 minute treatment (Fig. 3c,d), phosphorylated p42/p44 MAPKs accumulated markedly in the nucleus. A lower dose of bpV(phen) (100 µM) or treatment with a high concentration of the tyrosine phosphatase inhibitor sodium orthovanadate (20 mM) (Gordon, 1991) led to the nuclear accumulation of the phosphorylated forms of p42/p44 MAPKs with a slower time course (data not shown).
|
bpV(phen) is an inhibitor of tyrosine-specific phosphatases (Posner et al., 1994). However, to obtain a rapid effect we used high concentrations that may inhibit several types of phosphatases. To test the potential involvement of other classes of phosphatases, we treated 3 hour serum-stimulated cells for 15 minutes with three well-characterized inhibitors of serine/threonine-specific phosphatases. Under these conditions, the nuclear pool of p42/p44 MAPKs could not be reactivated by okadaic acid (1 µM), microcystin-LR (1 µM), nor cyclosporin A (8 µM) (data not shown).
Since sodium orthovanadate leads to inhibition of protein synthesis (Vinals et al., 2001), we tested whether bpV(phen) also alters protein synthesis. Indeed, in cells stimulated for 4 hours with 10% FCS, 1 mM bpV(phen) completely blocked protein synthesis, as potently as treatment with 30 µM cycloheximide (CHX) (data not shown). Nevertheless, treatment of 3 hour serum-stimulated cells for 15 minutes with 30 µM of CHX did not modify the nuclear signal with the anti-activated p42/p44 MAPKs antibody (Fig. 3f).
Taken together, these results indicate that the ability of bpV(phen) to trigger the rapid appearance of phosphorylated p42/p44 MAPKs in the nucleus is not mediated by reactivation of the p42/p44 MAPKs pathway, by inhibition of serine/threonine-specific phosphatases or protein synthesis, but most likely by a direct inhibition of tyrosine- or dual-specific phosphatases (also sensitive to orthovanadate) (Muda et al., 1997).
The phosphatases that dephosphorylate p42/p44 MAPKs in the nucleus are neo-synthesized
To further characterize the phosphatases involved in the nuclear inactivation of p42/p44 MAPKs, we investigated the contribution of long-term protein synthesis on the nuclear inactivation of p42/p44 MAPKs. Treatment of serum-deprived cells with CHX for 3 hours by itself did not lead to the activation of p42/p44 MAPKs (data not shown) (Brondello et al., 1997; Lenormand et al., 1998). However, stimulation of the cells with 10% FCS for 3 hours in the presence of 30 µM of CHX had two marked effects: (1) suppression of nuclear accumulation of the p42/p44 MAPKs pool (compare Fig. 4a and Fig. 4b); (2) suppression of nuclear p42/p44 MAPKs inactivation (compare Fig. 4d and Fig. 4e). The same effects were observed with 5 µg/ml of actinomycin D, which inhibits transcription (Fig. 4c,f), thus excluding the possibility that the effects observed with CHX are due to an activation of other signaling pathways such as the stress kinase pathways.
|
The time course of nuclear p42/p44 MAPKs activation correlates with the phosphorylation of a nuclear p42/p44 MAPKs substrate: HIF-1
We interpreted the progressive decrease in the phospho-p42/p44 MAPKs signal in the nucleus monitored by immunostaining as an inactivation of nuclear p42/p44 MAPKs. However, to confirm this interpretation we followed the time course of phosphorylation of a nuclear substrate of p42/p44 MAPKs: the hypoxia-inducible factor 1 (HIF-1
) (Richard et al., 1999). HIF-1
was detectable only when quiescent
Raf1:ER cells were incubated in hypoxic conditions (Fig. 5, upper blot, compare lanes 1 and 2) and its phosphorylation was evaluated by its mobility shift on a western blot (Richard et al., 1999).
Raf1:ER cells were stimulated for different times before the end of a 5 hour hypoxic period. After 15 minutes of
Raf1:ER chimera stimulation, the mobility shift up of HIF-1
was detectable (Fig. 5, lane 3) but was maximal between 30 and 60 minutes of stimulation (Fig. 5, lanes 4,5) with an equal ratio between the unphosphorylated and the phosphorylated forms of HIF-1
. After 3 hours of
Raf1:ER chimera stimulation, nearly all of the HIF-1
migrated as the lower molecular weight band (unphosphorylated form; Fig. 5, lane 7). At that time, addition of bpV(phen) for 30 minutes triggered the shift up of the whole band (phosphorylated form; Fig. 5, lane 8), which correlates with the strong re-activation of nuclear p42/p44 MAPKs observed by immunofluorescence after such treatment (Fig. 3).
|
Finally, we followed the appearance of the nuclear phosphatases MKP1 and MKP2 (Fig. 5, lower blot). After 120 and 180 minutes of Raf1:ER chimera stimulation, the phosphatases were maximally induced, which correlates with the nuclear inactivation of p42/p44 MAPKs observed by immunofluorescence and with dephosphorylation of HIF-1
.
Therefore, the decrease in the nuclear phospho-p42/p44 MAPKs signal observed by immunofluorescence corresponds to a decline in the nuclear p42/p44 MAPKs activity, possibly due to the dephosphorylation of p42/p44 MAPKs by the dual specificity phosphatases MKP1 and MKP2.
The C-terminal peptide of p90rsk can disrupt the interaction of p42/p44 MAPKs with their nuclear phosphatases thus preventing nuclear p42/p44 MAPKs inactivation
To further characterize the phosphatases involved in the nuclear inactivation of p42/p44 MAPKs, we tested whether these phosphatases are specific and need to bind to the conserved docking site of p42/p44 MAPKs (Sharrocks et al., 2000; Tanoue et al., 2000). To test this hypothesis, we microinjected a peptide corresponding to the docking site for p42/p44 MAPKs on p90rsk (Gavin and Nebreda, 1999; Smith et al., 1999). This peptide has been shown in vitro to specifically inhibit MKP3 catalytic activation by p42/p44 MAPKs by disrupting the interaction between p42/p44 MAPKs and MKP3, thereby preventing p42/p44 MAPKs dephosphorylation (Nichols et al., 2000). As a control, we microinjected a peptide mutated on the critical residues for binding (Nichols et al., 2000) (Fig. 6A, green). The peptides were coupled to BSA to reduce diffusion after specific microinjection into the nucleus or into the cytoplasm. In an in vitro MKP3 activity assay, the BSA-coupled peptides behaved similarly to the free peptides (Fig. 6B). We then microinjected BSA-p90rskwt and BSA-p90rskmut peptides either into the nucleus or into the cytoplasm of REF52 cells after 2 hours of serum stimulation, when inactive p42/p44 MAPKs were maximally accumulated in the nucleus. The cells were fixed after a 20 minute recovery period in serum-containing medium. Microinjected cells were detected with an anti-BSA antibody (FITC labeling, green) and the phosphorylation of p42/p44 MAPKs was detected with the anti-activated p42/p44 MAPKs antibody (Alexa-594 labeling, red).
When microinjected into the nucleus (Fig. 6C), the BSA-p90rskwt peptide induced a reappearance of active nuclear p42/p44 MAPKs (Fig. 6Cc,d) compared with non-microinjected cells or cells microinjected with the BSA-p90rskmut peptide (Fig. 6Cf). Moreover, microinjection of the same BSA-coupled peptides into the cytoplasm (Fig. 6D) did not have any detectable effects on the phosphorylation of nuclear p42/p44 MAPKs (Fig. 6Db,d).
These experiments suggest that the phosphatases responsible for the nuclear inactivation of p42/p44 MAPKs are likely to be nuclear phosphatases that specifically bind to p42/p44 MAPKs through a conserved docking site, two features of MKP1 and MKP2.
p42/p44 MAPKs constantly shuttle between the nucleus and the cytoplasm
The rapid reappearance of nuclear phosphorylated p42/p44 MAPKs observed following treatment with bpV(phen) suggested that there was an efficient shuttling of p42/p44 MAPKs between the nucleus and the cytoplasm after 3 hours of serum stimulation.
To get more insight into this dynamic process, we analyzed the effects of Leptomycine B (LMB), an inhibitor of active nuclear export (Fukuda et al., 1997a), on p42/p44 MAPKs localization. In quiescent cells, p42/p44 MAPKs are sequestered in the cytoplasm (Fig. 7Aa). However, a 5 minute treatment with LMB was already sufficient to induce a weak nuclear accumulation of p42/p44 MAPKs (Fig. 7Ab). LMB does not activate the p42/p44 MAPKs pathway (data not shown) and the same accumulation was observed in the presence of the MEK inhibitor UO126 (data not shown). In cells stimulated with serum for 5 minutes we could not detect any nuclear accumulation of p42/p44 MAPKs (Fig. 7Ac), except when the stimulation was performed in the presence of LMB (Fig. 7Ad). Finally, after 3 hours of serum stimulation, p42/p44 MAPKs accumulated massively in the nucleus (Fig. 7Ba), and a 10 minute treatment with LMB reinforced this nuclear accumulation (Fig. 7Bb). Therefore, in quiescent as well as in serum-stimulated cells, there is a constant active export of p42/p44 MAPKs from the nucleus.
|
Therefore we propose that there is a permanent shuttling of p42/p44 MAPKs throughout stimulation. The mechanism mediating the nuclear import of p42/p44 MAPKs are not well understood yet. However, we show that nuclear accumulation of p42/p44 MAPKs requires MEK activity and that nuclear export is dependent on an active mechanism.
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Our study identified the phosphatases responsible for the nuclear inactivation of p42/p44 MAPKs as tyrosine- or dual-specific phosphatases inhibited by bpV(phen) treatment. Furthermore, we showed that these phosphatases are neo-synthesized in response to activation of the p42/p44 MAPKs pathway, as treatment with either CHX or actinomycine D during stimulation prevents the nuclear inactivation of p42/p44 MAPKs. Finally, using a peptide that corresponds to the specific docking site for p42/p44 MAPKs on their substrates and regulators (Tanoue et al., 2000), we reduced markedly nuclear p42/p44 MAPKs inactivation by disrupting the interaction between p42/p44 MAPKs and their nuclear phosphatases. We thus conclude that the nuclear phosphatases responsible for p42/p44 MAPKs nuclear inactivation need to specifically bind to this docking site in order to dephosphorylate and inactivate p42/p44 MAPKs. MKP1 and MKP2 are the only nuclear phosphatases described so far that have all these properties. They are two nuclear dual specificity phosphatases that show significant specificity towards p42/p44 MAPKs and that possess the consensus sequence for binding to p42/p44 MAPKs (Fig. 6A). Furthermore, they are specifically induced by the p42/p44 MAPKs pathway with a time course that correlates with the nuclear inactivation of p42/p44 MAPKs (Fig. 5) (Brondello et al., 1997). Finally, p42/p44 MAPKs phosphorylate MKP1 and MKP2, thereby slowing down their proteasome-dependent degradation (Brondello et al., 1999). Therefore, this enzymatic system constituted of p42/p44 MAPKs and MKP1/2 possesses all the attributes of an autoregulatory loop capable of setting the spatio-temporal activity of this pathway. However, we have not been able to ablate both MKP1 and MKP2 activity by classical antisense strategies (cDNA or oligonucleotides) to firmly establish that MKP1 and/or MKP2 are the phosphatases that dephosphorylate p42/p44 MAPKs in the nucleus. Moreover, the inactivation of the mkp1 gene does not modify the development of mice nor the time course of p42/p44 MAPKs activation (Dorfman et al., 1996). This suggests either that MKP1 does not play a key role or rather that other phosphatases such as MKP2 are able to compensate for the deficit in MKP1 in these mice. In lower eukaryotic organisms such as the worm Caenorhabditis elegans, which possesses less genetic redundancy, it has been shown that the MKP LIP-1 needs to be expressed in the nucleus to inhibit the RTK/RAS/MAPK signaling pathway and to fully induce a penetrant vulvaless phenotype (Berset et al., 2001). These studies strongly support the role of nuclear MKPs in the negative control of the RAS/MAPK signaling pathway.
Interestingly, this new role for the nucleus as a specific site for signal termination is likely to be conserved for other MAPK pathways. Indeed, McDonald et al., have recently characterized ß-arrestin 2 as a MAPK scaffold for the activation of JNK3 (McDonald et al., 2000). Although most of this study was done in cells overexpressing the different partners of the pathway, it clearly shows that activation triggers the nuclear accumulation of a GFP-JNK3 fusion protein but that no nuclear signal is detectable with the anti-phospho-JNK antibody. The authors do not discuss this observation but it might be a regulatory mechanism comparable with that of endogenous p42/p44 MAPKs (Pouyssegur, 2000). Indeed, nuclear MAPK phosphatases specific for the JNK and p38 MAPK pathway have also been identified (Camps et al., 2000; Keyse, 2000).
The present report gives a new view of the dynamics of p42/p44 MAPKs localization throughout stimulation as schematized in Fig. 8. Indeed, we show that p42/p44 MAPKs constantly and rapidly shuttle between the nucleus and the cytoplasm even in quiescent cells deprived of any residual p42/p44 MAPK activity by UO126 pretreatment. This is revealed by treating the cells with LMB, which blocks active nuclear export and induces the nuclear accumulation of p42/p44 MAPKs. This result is in accordance with the model proposed by Adachi et al., in which p42/p44 MAPKs are actively exported from the nucleus by a mechanism that depends on the nuclear export sequence of MEK (Adachi et al., 2000).
|
Interestingly, the permanent entry of phosphorylated p42/p44 MAPKs into the nucleus after long-term mitogenic stimulation might be sufficient to phosphorylate a very specific set of nuclear substrates. Indeed, nuclear MKP1 and MKP2 are phosphorylated by p42/p44 MAPKs at times when p42/p44 MAPKs are massively inactivated in the nucleus (Brondello et al., 1999). By contrast, substrates such as HIF-1 are phosphorylated in accordance with the time course of nuclear p42/p44 MAPKs activity (Fig. 5). These observations suggest that after long-term growth stimulation, p42/p44 MAPKs may discriminate between different substrates for specific phosphorylation. We are currently investigating this aspect of the spatio-temporal regulation of p42/p44 MAPKs activity.
![]() |
ACKNOWLEDGMENTS |
---|
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Adachi, M., Fukuda, M. and Nishida, E. (1999). Two co-existing mechanisms for nuclear import of MAP kinase: passive diffusion of a monomer and active transport of a dimer. EMBO J. 18, 5347-5358.
Adachi, M., Fukuda, M. and Nishida, E. (2000). Nuclear export of MAP kinase (ERK) involves a MAP kinase kinase (MEK)-dependent active transport mechanism. J. Cell Biol. 148, 849-856.
Alessi, D. R., Gomez, N., Moorhead, G., Lewis, T., Keyse, S. M. and Cohen, P. (1995). Inactivation of p42 MAP kinase by protein phosphatase 2A and a protein tyrosine phosphatase, but not CL100, in various cell lines. Curr. Biol. 5, 283-295.[Medline]
Anderson, N. G., Maller, J. L., Tonks, N. K. and Sturgill, T. W. (1990). Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 343, 651-653.[Medline]
Bardwell, L., Cook, J. G., Chang, E. C., Cairns, B. R. and Thorner, J. (1996). Signaling in the yeast pheromone response pathway: specific and high-affinity interaction of the mitogen-activated protein (MAP) kinases Kss1 and Fus3 with the upstream MAP kinase kinase Ste7. Mol. Cell. Biol. 16, 3637-3650.[Abstract]
Bardwell, L. and Thorner, J. (1996). A conserved motif at the amino termini of MEKs might mediate high-affinity interaction with the cognate MAPKs. Trends Biochem. Sci. 21, 373-374.[Medline]
Berset, T., Hoier, E. F., Battu, G., Canevascini, S. and Hajnal, A. (2001). Notch inhibition of RAS signaling through MAP kinase phosphatase LIP-1 during C. elegans vulval development. Science 291, 1055-1058.
Bevan, A. P., Burgess, J. W., Drake, P. G., Shaver, A., Bergeron, J. J. and Posner, B. I. (1995). Selective activation of the rat hepatic endosomal insulin receptor kinase. Role for the endosome in insulin signaling. J. Biol. Chem. 270, 10784-10791.
Brondello, J. M., McKenzie, F. R., Sun, H., Tonks, N. K. and Pouyssegur, J. (1995). Constitutive MAP kinase phosphatase (MKP-1) expression blocks G1 specific gene transcription and S-phase entry in fibroblasts. Oncogene 10, 1895-1904.[Medline]
Brondello, J. M., Brunet, A., Pouyssegur, J. and McKenzie, F. R. (1997). The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. J. Biol. Chem. 272, 1368-1376.
Brondello, J. M., Pouyssegur, J. and McKenzie, F. R. (1999). Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science 286, 2514-2517.
Brunet, A., Roux, D., Lenormand, P., Dowd, S., Keyse, S. and Pouyssegur, J. (1999). Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J. 18, 664-674.
Camps, M., Nichols, A. and Arkinstall, S. (2000). Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J. 14, 6-16.
Chen, R. H., Sarnecki, C. and Blenis, J. (1992). Nuclear localization and regulation of erk- and rsk-encoded protein kinases. Mol. Cell. Biol. 12, 915-927.[Abstract]
Dorfman, K., Carrasco, D., Gruda, M., Ryan, C., Lira, S. A. and Bravo, R. (1996). Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene 13, 925-931.[Medline]
Feldherr, C. M. and Akin, D. (1993). Regulation of nuclear transport in proliferating and quiescent cells. Exp. Cell Res. 205, 179-186.[Medline]
Fukuda, M., Asano, S., Nakamura, T., Adachi, M., Yoshida, M., Yanagida, M. and Nishida, E. (1997a). CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390, 308-311.[Medline]
Fukuda, M., Gotoh, I., Adachi, M., Gotoh, Y. and Nishida, E. (1997b). A novel regulatory mechanism in the mitogen-activated protein (MAP) kinase cascade. Role of nuclear export signal of MAP kinase kinase. J. Biol. Chem. 272, 32642-32648.
Fukuda, M., Gotoh, Y. and Nishida, E. (1997c). Interaction of MAP kinase with MAP kinase kinase: its possible role in the control of nucleocytoplasmic transport of MAP kinase. EMBO J. 16, 1901-1908.
Gavin, A. C. and Nebreda, A. R. (1999). A MAP kinase docking site is required for phosphorylation and activation of p90(rsk)/MAPKAP kinase-1. Curr. Biol. 9, 281-284.[Medline]
Gordon, J. A. (1991). Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol. 201, 477-482.[Medline]
Guan, K. L. (1994). The mitogen activated protein kinase signal transduction pathway: from the cell surface to the nucleus. Cell Signal. 6, 581-589.[Medline]
Kahan, C., Seuwen, K., Meloche, S. and Pouyssegur, J. (1992). Coordinate, biphasic activation of p44 mitogen-activated protein kinase and S6 kinase by growth factors in hamster fibroblasts. Evidence for thrombin-induced signals different from phosphoinositide turnover and adenylylcyclase inhibition. J. Biol. Chem. 267, 13369-13375.
Keyse, S. M. (2000). Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr. Opin. Cell Biol. 12, 186-192.[Medline]
Khokhlatchev, A. V., Canagarajah, B., Wilsbacher, J., Robinson, M., Atkinson, M., Goldsmith, E. and Cobb, M. H. (1998). Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell 93, 605-615.[Medline]
Kim-Kaneyama, J., Nose, K. and Shibanuma, M. (2000). Significance of nuclear relocalization of ERK1/2 in reactivation of c-fos transcription and DNA synthesis in senescent fibroblasts. J. Biol. Chem. 275, 20685-20692.
Lenormand, P., Brondello, J. M., Brunet, A. and Pouyssegur, J. (1998). Growth factor-induced p42/p44 MAPK nuclear translocation and retention requires both MAPK activation and neosynthesis of nuclear anchoring proteins. J. Cell Biol. 142, 625-633.
Lenormand, P., McMahon, M. and Pouyssegur, J. (1996). Oncogenic Raf-1 activates p70 S6 kinase via a mitogen-activated protein kinase-independent pathway. J. Biol. Chem. 271, 15762-15768.
Lenormand, P., Sardet, C., Pages, G., LAllemain, G., Brunet, A. and Pouyssegur, J. (1993). Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts. J. Cell Biol. 122, 1079-1088.[Abstract]
Lewis, T. S., Shapiro, P. S. and Ahn, N. G. (1998). Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74, 49-139.[Medline]
Mattison, C. P. and Ota, I. M. (2000). Two protein tyrosine phosphatases, Ptp2 and Ptp3, modulate the subcellular localization of the Hog1 MAP kinase in yeast. Genes Dev. 14, 1229-1235.
McDonald, P. H., Chow, C. W., Miller, W. E., Laporte, S. A., Field, M. E., Lin, F. T., Davis, R. J. and Lefkowitz, R. J. (2000). beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 290, 1574-1577.
Meloche, S., Seuwen, K., Pages, G. and Pouyssegur, J. (1992). Biphasic and synergistic activation of p44mapk (ERK1) by growth factors: correlation between late phase activation and mitogenicity. Mol. Endocrinol. 6, 845-854.[Abstract]
Muda, M., Boschert, U., Smith, A., Antonsson, B., Gillieron, C., Chabert, C., Camps, M., Martinou, I., Ashworth, A. and Arkinstall, S. (1997). Molecular cloning and functional characterization of a novel mitogen-activated protein kinase phosphatase, MKP-4. J. Biol. Chem. 272, 5141-5151.
Nichols, A., Camps, M., Gillieron, C., Chabert, C., Brunet, A., Wilsbacher, J., Cobb, M., Pouyssegur, J., Shaw, J. P. and Arkinstall, S. (2000). Substrate recognition domains within extracellular signal-regulated kinase mediate binding and catalytic activation of mitogen-activated protein kinase phosphatase-3. J. Biol. Chem. 275, 24613-24621.
Oh-hora, M., Ogata, M., Mori, Y., Adachi, M., Imai, K., Kosugi, A. and Hamaoka, T. (1999). Direct suppression of TCR-mediated activation of extracellular signal-regulated kinase by leukocyte protein tyrosine phosphatase, a tyrosine-specific phosphatase. J. Immunol. 163, 1282-1288.
Payne, D. M., Rossomando, A. J., Martino, P., Erickson, A. K., Her, J. H., Shabanowitz, J., Hunt, D. F., Weber, M. J. and Sturgill, T. W. (1991). Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J. 10, 885-892.[Abstract]
Pettiford, S. M. and Herbst, R. (2000). The MAP-kinase ERK2 is a specific substrate of the protein tyrosine phosphatase HePTP. Oncogene 19, 858-869.[Medline]
Posner, B. I., Faure, R., Burgess, J. W., Bevan, A. P., Lachance, D., Zhang-Sun, G., Fantus, I. G., Ng, J. B., Hall, D. A., Lum, B. S. et al. (1994). Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J. Biol. Chem. 269, 4596-4604.
Pouyssegur, J. (2000). Signal transduction. An arresting start for MAPK. Science 290, 1515-1518.
Pulido, R., Zuniga, A. and Ullrich, A. (1998). PTP-SL and STEP protein tyrosine phosphatases regulate the activation of the extracellular signal-regulated kinases ERK1 and ERK2 by association through a kinase interaction motif. EMBO J. 17, 7337-7350.
Reiser, V., Ammerer, G. and Ruis, H. (1999). Nucleocytoplasmic traffic of MAP kinases. Gene Expr. 7, 247-254.[Medline]
Richard, D. E., Berra, E., Gothie, E., Roux, D. and Pouyssegur, J. (1999). p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 274, 32631-32637.
Robinson, M. J. and Cobb, M. H. (1997). Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9, 180-186.[Medline]
Robinson, M. J., Stippec, S. A., Goldsmith, E., White, M. A. and Cobb, M. H. (1998). A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr. Biol. 8, 1141-1150.[Medline]
Samuels, M. L., Weber, M. J., Bishop, J. M. and McMahon, M. (1993). Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human raf-1 protein kinase. Mol. Cell. Biol. 13, 6241-6252.[Abstract]
Saxena, M., Williams, S., Brockdorff, J., Gilman, J. and Mustelin, T. (1999). Inhibition of T cell signaling by mitogen-activated protein kinase-targeted hematopoietic tyrosine phosphatase (HePTP). J. Biol. Chem. 274, 11693-11700.
Seuwen, K., Kahan, C., Hartmann, T. and Pouyssegur, J. (1990). Strong and persistent activation of inositol lipid breakdown induces early mitogenic events but not Go to S phase progression in hamster fibroblasts. Comparison of thrombin and carbachol action in cells expressing M1 muscarinic acetylcholine receptors. J. Biol. Chem. 265, 22292-22299.
Sharrocks, A. D., Yang, S. H. and Galanis, A. (2000). Docking domains and substrate-specificity determination for MAP kinases. Trends Biochem. Sci. 25, 448-453.[Medline]
Smith, J. A., Poteet-Smith, C. E., Malarkey, K. and Sturgill, T. W. (1999). Identification of an extracellular signal-regulated kinase (ERK) docking site in ribosomal S6 kinase, a sequence critical for activation by ERK in vivo. J. Biol. Chem. 274, 2893-2898.
Sohaskey, M. L. and Ferrell, J. E. (1999). Distinct, constitutively active MAPK phosphatases function in Xenopus oocytes: implications for p42 MAPK regulation In vivo. Mol. Biol. Cell 10, 3729-3743.
Tanoue, T., Adachi, M., Moriguchi, T. and Nishida, E. (2000). A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat. Cell Biol. 2, 110-116.[Medline]
Vinals, F., McKenzie, F. R. and Pouyssegur, J. (2001). Growth factor-stimulated protein synthesis is inhibited by sodium orthovanadate. Eur. J. Biochem. 268, 1-8.
Vouret-Craviari, V., Van Obberghen-Schilling, E., Scimeca, J. C., Van Obberghen, E. and Pouyssegur, J. (1993). Differential activation of p44mapk (ERK1) by alpha-thrombin and thrombin-receptor peptide agonist. Biochem. J. 289, 209-214.[Medline]
Yung, Y., Dolginov, Y., Yao, Z., Rubinfeld, H., Michael, D., Hanoch, T., Roubini, E., Lando, Z., Zharhary, D. and Seger, R. (1997). Detection of ERK activation by a novel monoclonal antibody. FEBS Lett. 408, 292-296.[Medline]
Zuniga, A., Torres, J., Ubeda, J. and Pulido, R. (1999). Interaction of mitogen-activated protein kinases with the kinase interaction motif of the tyrosine phosphatase PTP-SL provides substrate specificity and retains ERK2 in the cytoplasm. J. Biol. Chem. 274, 21900-21907.